Yu Xia is listed as a director on 2 SEC Form D filings by 1 issuer between Jun 2024 and Sep 2024: Summit Therapeutics Inc. (Miami, FL — biotechnology — 2024; $235M reported sold to 17 investors).
What this means One deal on file with the SEC, filed Sep 2024. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Alessandra Cesano (2 shared filings), Kenneth Clark (2 shared filings), Mahkam Zanganeh (2 shared filings), Manmeet Soni (2 shared filings), Mostafa Ronaghi (2 shared filings) and 4 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Yu. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, LA, ME, MO, MS, MT, NASAA, NC, NH, NM, OR, RI, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Yu Xia and found 1 difference, 1 worth asking the sponsor about: 32% of the money raised went to insiders.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.